I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19

E-mail:?jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000 Gigi Feng, Chief Communications Officer
E-mail:?gigi.feng@i-mabbiopharma.com??
Office line: +86 21 6057 5709 Investor Inquiries: The Piacente Group, Inc.
Emilie Wu
E-mail:?emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363 SOURCE I-Mab
